Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

The results come from Part 1 of the ESSENCE trial, which involved around 800 patients treated with semaglutide or placebo on top of standard care and followed for 72 weeks. MASH is a form of non ...

Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...

Hims & Hers’ Super Bowl ad plugs its compounded weight loss drugs as the “affordable” solution to a “sick system,” but many concerns about safety still swirl around these forms of the ...